Data42
Data42 is a biopharmaceutical data initiative launched by Novartis in 2020 to consolidate and analyze its vast clinical and research datasets.
Profile
Aggregates and analyzes pharmaceutical research data to accelerate drug discovery.
Data42 is a biopharmaceutical data initiative launched by Novartis in 2020 to consolidate and analyze its vast clinical and research datasets. The program aggregates over 2 million patient-years of data and 20 petabytes of R&D information, including clinical trials, real-world evidence, and genomic data, into a unified platform. Originally positioned as an internal moonshot project to accelerate drug discovery, Data42 has since expanded to include partnerships with academic institutions and biotech firms.
The initiative aims to apply machine learning to identify novel drug-disease correlations, with early focus areas including myelofibrosis and rare diseases. Novartis has not disclosed specific revenue figures for Data42, but the parent company allocated $300M annually for digital transformation initiatives as of 2024. The program faces technical challenges in standardizing disparate datasets across 200+ clinical studies and legacy systems. Recent moves include the 2024 acquisition of MorphoSys AG for €2.7B to bolster its oncology data assets, particularly around the pelabresib BET inhibitor program.
Who buys this
- Novartis internal R&D teams
- Academic medical research partners
- Biotech companies with data-sharing agreements
- Regulatory agencies receiving curated datasets
Strengths and what to watch
Strengths
- Access to Novartis' proprietary dataset of 2M+ patient-years across therapeutic areas
- Established infrastructure with 20PB of structured clinical trial data
- Backing by Novartis' $300M annual digital transformation budget
Watch for
- Dependence on Novartis funding with no independent revenue model disclosed
- Data standardization challenges across 200+ legacy clinical study formats
- Regulatory scrutiny around patient privacy for real-world evidence applications
Key Information
- Founded
- 2020
Frequently Asked Questions
What is Data42 in pharmaceuticals?
Data42 is Novartis' initiative launched in 2020 to consolidate clinical research data. It aggregates over 2 million patient-years and 20 petabytes of R&D information, including trials and genomic data, to accelerate drug discovery through machine learning analysis, focusing on areas like myelofibrosis and rare diseases.
How big is Data42's clinical dataset?
Data42's repository contains over 2 million patient-years of clinical data across 200+ studies, plus 20 petabytes of structured R&D information. This includes Novartis' proprietary trial data, real-world evidence, and genomic datasets standardized through their platform for research applications.
Why did Novartis acquire MorphoSys for Data42?
Novartis acquired MorphoSys AG in 2024 for €2.7B primarily to enhance Data42's oncology data assets. The deal specifically bolstered their pelabresib BET inhibitor program, adding valuable cancer research datasets to Novartis' existing pharmaceutical data infrastructure.
Who uses Data42's research platform?
Primary users include Novartis' internal R&D teams, academic medical researchers, biotech partners with data-sharing agreements, and regulatory agencies receiving curated datasets. The platform serves organizations needing access to large-scale, standardized pharmaceutical research data for discovery applications.
What are Data42's main technical challenges?
Data42 faces significant hurdles standardizing 200+ disparate clinical study formats across legacy systems. The initiative also manages privacy compliance for real-world evidence applications while maintaining data utility for machine learning analysis in drug discovery pipelines.
How is Novartis funding Data42?
Novartis allocates $300M annually from its digital transformation budget to Data42, though no independent revenue model exists. Funding supports data infrastructure, partnerships like academic collaborations, and strategic acquisitions such as MorphoSys to expand therapeutic datasets.
Sources
- www.novartis.com — 2M patient-years data and 20PB R&D data volume
- www.novartis.com — MorphoSys acquisition for oncology data assets
- www.sec.gov — Financial context of Novartis acquisitions
- www.data42.de — Operational presence and focus areas